In malignant high-grade gliomas, neuronal activity leverages the ADAM10/neuroligin-3 axis to drive tumor growth [98,99], which has led to a clinical trial that evaluates an ADAM10 inhibitor (INCB7839) in treating recurrent or progressive pediatric high-grade gliomas (NCT04295759). Here, ADAM10 is linked to neoplasm.